Overview

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, blinded, placebo-controlled study in up to 20 overweight or obese participants with type 2 diabetes mellitus. The participants will participate in the study for approximately 18 weeks, including screening, run-in and treatment periods and a safety follow-up.
Phase:
Phase 2
Details
Lead Sponsor:
MedImmune LLC